-+ 0.00%
-+ 0.00%
-+ 0.00%

LifeSci Capital Downgrades Ventyx Biosciences to Market Perform, Announces $14 Price Target

Benzinga·01/08/2026 12:17:37
語音播報
LifeSci Capital analyst Sam Slutsky downgrades Ventyx Biosciences (NASDAQ:VTYX) from Outperform to Market Perform and announces $14 price target.